Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (464)	2/24/2005 8:33:39 PM
From: Ian@SI	Read Replies (1) of 946

In Message 20932102 , MJ says, "My memory on 2103 PK is going back to 2000/2001. It was one report-note (I found it online), but now I can not find even print copy ... Never saw complete PK data (urine content). ...". He also provides links to PH 1 study abstracts which seem to disagree with his memory. In the first abstract posted is the statement, "Peak concentrations of unconjugated paclitaxel in plasma varied from 0.06 to 2.48µM, but were less than the threshold concentration for toxicity of 0.1µM 24 hours after CT-2103 administration at doses up to 480mg/m2. The patient at 720mg/m2 who experienced Grade 4 toxicity had prolonged elevated plasma concentrations of paclitaxel (0.53µM at 24 hr) and remained above 0.1µM for over 48 hours.". Is this inconsistent with the drug being active in tumours?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next